[Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma].
OBJECTIVE
To analyze the clinico-pathological characteristics, prognostic factors and the rational therapy for the uterine papillary serous carcinoma (UPSC).


METHODS
Thirty-three cases of UPSC were treated in our hospital between January 1996 and December 2005. The clinico-pathologic characteristics, treatment and prognosis were retrospectively analyzed.


RESULTS
The three-year overall survival for patients with stage I, III and IV was 77.4%, 53.3% and 12.1%, respectively. Patients with late stages and deep myometrial invasion were associated with a worse prognosis by univariate analysis (P < 0.05), while in a multivariate analysis only late stages and poor differentiation were associated with a poor prognosis (P < 0.05). The prognosis of patients in late stages treated with postoperative chemotherapy was significantly better than those without chemotherapy (P = 0.014).


CONCLUSIONS
Most UPSC patients are in late stages at diagnosis. They often have extra-uterine metastasis and have a poor prognosis. Complete surgical staging is recommended, and postoperative chemotherapy seems to improve the prognosis.
Ren
Yu-Lan
YL
Department of Gynecologic Oncology, Tumor Hospital, Fudan University, Shanghai 200032, China.
Wang
Hua-Ying
HY
Shen
Lei
L
Yang
Wen-Tao
WT
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
D015251:Epirubicin; D002945:Cisplatin